Have a feature idea you'd love to see implemented?
Let us know!
MEIP MEI Pharma Inc
Price (delayed)
$2.75
Market cap
$18.32M
P/E Ratio
1.03
Dividend/share
$1.75
EPS
$2.67
Enterprise value
$14.62M
MEI Pharma, Inc. is a late-stage pharmaceutical company focused on developing potential new therapies for cancer. MEI Pharma's portfolio of drug candidates contains four clinical-stage assets, including zandelisib, currently in
Highlights
MEI Pharma's debt has shrunk by 100% QoQ and by 100% YoY
MEIP's P/E is 21% below its last 4 quarters average of 1.3
MEIP's net income has surged by 156% year-on-year but it is down by 32% since the previous quarter
The EPS has soared by 156% YoY but it has contracted by 32% from the previous quarter
The company's quick ratio fell by 22% QoQ and by 7% YoY
Key stats
What are the main financial stats of MEIP
Market
Valuations
Earnings
Shares outstanding
6.66M
Market cap
$18.32M
Enterprise value
$14.62M
Price to earnings (P/E)
1.03
Price to book (P/B)
0.55
Price to sales (P/S)
0.28
EV/EBIT
0.82
EV/EBITDA
0.71
EV/Sales
0.22
Revenue
$65.3M
EBIT
$17.78M
EBITDA
$20.59M
Free cash flow
-$50.48M
Per share
Balance sheet
Liquidity
EPS
$2.67
Free cash flow per share
-$7.58
Book value per share
$4.96
Revenue per share
$9.8
TBVPS
$6.21
Total assets
$41.38M
Total liabilities
$8.36M
Debt
$0
Equity
$33.02M
Working capital
$32.41M
Debt to equity
0
Current ratio
4.88
Quick ratio
4.59
Net debt/EBITDA
-0.18
Margins
Efficiency
Dividend
EBITDA margin
31.5%
Gross margin
100%
Net margin
27.2%
Operating margin
22.3%
Return on assets
24.3%
Return on equity
31.6%
Return on invested capital
25.5%
Return on capital employed
53.8%
Return on sales
27.2%
Dividend yield
63.64%
DPS
$1.75
Payout ratio
65.5%
MEIP stock price
How has the MEI Pharma stock price performed over time
Intraday
-0.72%
1 week
1.85%
1 month
-8.33%
1 year
-59.68%
YTD
-52.59%
QTD
-3.51%
Financial performance
How have MEI Pharma's revenue and profit performed over time
Revenue
$65.3M
Gross profit
$65.3M
Operating income
$14.54M
Net income
$17.78M
Gross margin
100%
Net margin
27.2%
MEIP's net income has surged by 156% year-on-year but it is down by 32% since the previous quarter
MEI Pharma's net margin has surged by 142% YoY but it has decreased by 31% QoQ
The operating income has soared by 140% YoY but it has contracted by 35% from the previous quarter
The operating margin has soared by 130% YoY but it has contracted by 34% from the previous quarter
Growth
What is MEI Pharma's growth rate over time
Valuation
What is MEI Pharma stock price valuation
P/E
1.03
P/B
0.55
P/S
0.28
EV/EBIT
0.82
EV/EBITDA
0.71
EV/Sales
0.22
The EPS has soared by 156% YoY but it has contracted by 32% from the previous quarter
MEIP's P/E is 21% below its last 4 quarters average of 1.3
The stock's price to book (P/B) is 82% less than its 5-year quarterly average of 3.0 and 8% less than its last 4 quarters average of 0.6
The equity fell by 35% QoQ but it rose by 34% YoY
MEIP's P/S is 97% below its 5-year quarterly average of 8.2 and 30% below its last 4 quarters average of 0.4
MEIP's revenue is up by 34% YoY but it is down by 2.2% QoQ
Efficiency
How efficient is MEI Pharma business performance
The ROS has soared by 142% YoY but it has contracted by 31% from the previous quarter
The ROE has soared by 136% YoY but it fell by 35% QoQ
MEI Pharma's ROIC has soared by 128% YoY but it has decreased by 16% from the previous quarter
MEIP's return on assets is down by 14% since the previous quarter
Dividends
What is MEIP's dividend history
DPS
$1.75
Dividend yield
63.64%
Payout ratio
65.5%
Recent dividends
Special dividends are included in TTM DPS and yield
Financial health
How did MEI Pharma financials performed over time
The total liabilities has plunged by 91% YoY and by 59% from the previous quarter
The total assets has dropped by 66% year-on-year and by 42% since the previous quarter
MEI Pharma's debt is 100% lower than its equity
MEI Pharma's debt to equity has shrunk by 100% QoQ and by 100% YoY
MEI Pharma's debt has shrunk by 100% QoQ and by 100% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.